AI-generated summary
The authors report a randomized, double-blind, placebo-controlled phase III trial of preventive low-level laser therapy in 94 head and neck cancer patients receiving chemoradiotherapy. The laser group had a lower incidence of grade 3-4 oral mucositis (6.4% versus 40.5% with placebo), and quality-of-life scores were reported to favor the laser group.
- Participants
- 94
- Who or what was studied
- Patients with head and neck squamous cell carcinoma receiving concurrent cisplatin and radiotherapy
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract does not describe the study's sample size calculation or follow-up duration, and the reported quality-of-life differences are not quantified.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660nm
- Power
- 100mW
- Total energy
- 1J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Oral mucositis, Laser, GRADE, Placebo-controlled. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.